What are the specifications of Platinib?

Pralsetinib (Pralsetinib) is a second-generation selective RET kinase inhibitor being developed by Blueprint Medicines. It is the patented compound 130. The U.S. Food and Drug Administration (FDA) approved platinib for the treatment of non-small cell lung cancer (NSCLC) in September 2020, and accelerated approval for the treatment of thyroid cancer in December 2020. Platinib is available100 mg in bottles of 60, 90, and 120 capsules.

Selective RET inhibitors have oncological potential for the treatment of solid tumors with oncogenic RET alterations, such as constitutively activating RET point mutations and RET gene rearrangements. They are expected to provide more potent anti-tumor efficacy in RET-driven tumors compared with currently available multi-kinase inhibitors such as cabozantinib and vandetanib, which have limited anti-RET activity and exhibit poor therapeutic responses in this specific patient population.

The original drug Platinib has been launched in China, but it has not yet passed the relevant policies for inclusion in medical insurance. The price of 120 pills per box may be around 60,000 yuan. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. Generic Platinib drugs are also available for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. The price of 120 pills per box produced by a Lao pharmaceutical factory may be more than 4,000 yuan (the price may fluctuate due to exchange rate effects).